A carregar...
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis
Bevacizumab is the first-in-class antiangiogenic drug and is almost always administrated in combination with cytotoxics. Reports have shown that bevacizumab could induce a transient phase of vascular normalization, thus ensuring a better drug delivery when cytotoxics administration is adjuvant. Howe...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5410287/ https://ncbi.nlm.nih.gov/pubmed/28416742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15484 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|